NIH R01 · 2024
Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia
ABSTRACT Approximately 100,000 women per year are diagnosed with atypical hyperplasia (AH) of the breast, a benign breast lesion that is associated with a fourfold increase in risk of subsequent breast cancer. Usage of tamoxifen as cancer prevention therapy following AH diagnosis has been linked to a greater than 50% reduction in subsequent breast cancer incidence. However, uptake of tamoxifen and similar prevention therapies remains low, due in part to a lack of methods to accurately determine which women are at greatest risk for breast cancer (BC), and which women will have a beneficial response to prevention therapy. We propose a highly translational project to address these critical…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.